Gaia Vince reports on research by Larry Steinman of Stanford and Michael Platten of the University of Tübingen
into a novel treatment for multiple sclerosis. Oral administration of synthetic kynurenines suppressed an analogous disease in lab mice and slowed its progression.
The mice on the tablets also had "re-programmed" T-cell function, [says Platten]: "Instead of being pro-inflammatory, the T-cells became anti-inflammatory, helping to heal the myelin sheath and suppressing paralysis."
It's possible that clinical trials could begin as early as 2006.
posted:
12:15:16 AM
|